{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:50:29Z","timestamp":1791409829648,"version":"4.3.3"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.09.021","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:57:45Z","timestamp":1789253865000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Severe Acute Graft-Versus-Host Disease Refractory to Multiple Lines of Therapy: Real-World Data from 317 Adults Treated with the Multiple-Donor Bone Marrow-Derived Mesenchymal Stromal Cell Preparation Tomostrocel"],"prefix":"10.1016","author":[{"given":"Mareike","family":"Verbeek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-2675","authenticated-orcid":false,"given":"Halvard","family":"Bonig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2359-131X","authenticated-orcid":false,"given":"Gesine","family":"Bug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"D\u2019Aveni-Piney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Herhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5543-0257","authenticated-orcid":false,"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Kos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-3632","authenticated-orcid":false,"given":"William","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Lupo-Stanghellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3134-9567","authenticated-orcid":false,"given":"Charlotte","family":"Neuerburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Osswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-6391","authenticated-orcid":false,"given":"Victoria","family":"Panagiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Reicherts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7070-487X","authenticated-orcid":false,"given":"Christoph","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha","family":"Srour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tribanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Wortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Zens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.09.021_bib0001","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.09.021_bib0002","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41409-019-0771-2","article-title":"Incorporating posttransplant cyclophosphamide based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature","volume":"55","author":"Garcia-Cadenas","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jtct.2026.09.021_bib0003","article-title":"Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Luo","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.09.021_bib0004","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American society of blood and marrow transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"10.1016\/j.jtct.2026.09.021_bib0005","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1007\/s00277-025-06491-y","article-title":"Successful treatment with mesenchymal stromal cells-Frankfurt am Main in a pediatric patient with steroid-refractory and ruxolitinib-refractory acute gastrointestinal graft-versus-host disease","volume":"104","author":"Ernst","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2026.09.021_bib0006","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00277-024-05952-0","article-title":"Recent advances in acute gastrointestinal graft versus host disease (aGVHD): aspects of steroid-resistant disease","volume":"104","author":"Kujawska","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2026.09.021_bib0007","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.17700","article-title":"Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease\u2014a real-world outcomes analysis","volume":"195","author":"Abedin","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.09.021_bib0008","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Le Blanc","year":"2004","journal-title":"Lancet"},{"issue":"9624","key":"10.1016\/j.jtct.2026.09.021_bib0009","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.021_bib0010","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.bbmt.2010.04.014","article-title":"Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study","volume":"17","author":"Prasad","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.09.021_bib0011","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.tp.0000214462.63943.14","article-title":"Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease","volume":"81","author":"Ringden","year":"2006","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.021_bib0012","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bmt.2017.35","article-title":"Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III\/IV after hematopoietic stem cell transplantation","volume":"52","author":"Dotoli","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.021_bib0013","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/bmt.2016.317","article-title":"Good responses but high TRM in adult patients after MSC therapy for GvHD","volume":"52","author":"Salmenniemi","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.021_bib0014","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/stem.2224","article-title":"Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome","volume":"34","author":"Von Dalowski","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.jtct.2026.09.021_bib0015","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(15)00224-0","article-title":"Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis","volume":"3","author":"Hashmi","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.09.021_bib0016","unstructured":"Australian Public Assessment Report for Remestemcel-L, Ex Vivo Adult Human Mesenchymal Stem Cells. 2019. Accessed 19 February 2026. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-remestemcel-l-150315.pdf."},{"issue":"17","key":"10.1016\/j.jtct.2026.09.021_bib0017","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO-24-02119","article-title":"Sequential infusion of mesenchymal stem cell for graft-versus-host disease prevention in haploidentical hematopoietic stem cell transplantation: an open-label, multicenter, randomized controlled clinical trial","volume":"43","author":"Yao","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.09.021_bib0018","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3324\/haematol.2015.140368","article-title":"Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease a multicenter survey","volume":"101","author":"Kuci","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.09.021_bib0019","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.bbmt.2018.07.015","article-title":"Manufacturing mesenchymal stromal cells for the treatment of graft-versus-host disease: a survey among centers affiliated with the European Society for Blood and Marrow Transplantation","volume":"24","author":"Trento","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.09.021_bib0020","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3324\/haematol.2013.092700","article-title":"Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression","volume":"98","author":"Ku\u00e7i","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.021_bib0021","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3390\/cells9020431","article-title":"The phenotype and functional activity of mesenchymal stromal cells in pediatric patients with non-malignant hematological diseases","volume":"9","author":"Kuci","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.021_bib0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12967-023-04684-5","article-title":"Expression of HLA-DR by mesenchymal stromal cells in the platelet lysate era: an obsolete release criterion for MSCs?","volume":"22","author":"Ku\u00e7i","year":"2024","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.021_bib0023","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"issue":"22","key":"10.1016\/j.jtct.2026.09.021_bib0024","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1182\/bloodadvances.2025017116","article-title":"The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD","volume":"9","author":"Akahoshi","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.021_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.021_bib0026","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3390\/cells8121577","article-title":"Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation \"MSC-FFM\"-outcome report of 92 patients","volume":"8","author":"Bonig","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.021_bib0027","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13287-020-01592-z","article-title":"Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis","volume":"11","author":"Morata-Tarifa","year":"2020","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.021_bib0028","article-title":"Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in hematopoietic stem cell transplant (HSCT) recipients with a haematological condition","volume":"1","author":"Fisher","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtct.2026.09.021_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.724380","article-title":"Treatment of steroid-refractory acute graft-versus-host disease using commercial mesenchymal stem cell products","volume":"12","author":"Murata","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.021_bib0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jcyt.2025.01.005","article-title":"ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells","volume":"27","author":"Blanc","year":"2025","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.021_bib0031","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2020.01.026","article-title":"Study 275: updated expanded access program for remestemcel-L in steroid-refractory acute graft-versus-host disease in children","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.021_bib0032","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.bbmt.2019.08.029","article-title":"A phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease","volume":"26","author":"Kebriaei","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.021_bib0033","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41409-021-01304-y","article-title":"Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence","volume":"56","author":"Murata","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.021_bib0034","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2026.300837","article-title":"Real-world outcomes of the mesenchymal stromal cell product tomostrocel in heavily pretreated pediatric patients with refractory acute graft-versus-host disease","author":"Vogelsang","year":"2026","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jtct.2026.09.021_bib0035","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41409-022-01741-3","article-title":"Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract","volume":"57","author":"Biavasco","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.09.021_bib0036","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/bmt.2013.59","article-title":"Prognosis of grade 3\u20134 acute GVHD continues to be dismal","volume":"48","author":"Jamani","year":"2013","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726007268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:02:58Z","timestamp":1791406978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726007268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":36,"alternative-id":["S2666636726007268"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.021","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Severe Acute Graft-Versus-Host Disease Refractory to Multiple Lines of Therapy: Real-World Data from 317 Adults Treated with the Multiple-Donor Bone Marrow-Derived Mesenchymal Stromal Cell Preparation Tomostrocel","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}